<DOC>
	<DOCNO>NCT01631058</DOCNO>
	<brief_summary>An exploratory study efficacy safety regimen consist Everolimus plus low tacrolimus immunosuppression renal transplantation elderly . To evaluate pharmacokinetics immunosuppressant little studied population . To evaluate whether polymorphism gene determine expression metabolize enzyme transporter xenobiotics interfere elderly , also young population , absorption metabolism immunosuppressant . To evaluate potential minimization immunosuppression population refers re-population peripheral lymphocyte , age group , use lymphocyte-depleting agent thymoglobulin subsequently maintain two regime . Clarify marker renal filtration exist today , cystatin C serum creatinine , right monitor renal function elderly transplant .</brief_summary>
	<brief_title>Renal Transplantation Elderly - nEverOld Study</brief_title>
	<detailed_description>Objectives : The objective study evaluate safety efficacy everolimus ( EVL ) combine low dose Tacrolimus comparison Mycophenolate Sodium ( MPS ) combine standard dose Tacrolimus immunosuppressive therapy elderly recipient kidney transplantation . Comparison two study arm : Primary Objective : 1 . Composite efficacy failure demonstrate graft loss and/or death functional graft and/or GFR ( Glomerular Filtration Rate determine EDTA-Cr51 ) &lt; 50 ml/min end first year transplantation every year fifth year . Secondary Objectives : 1 . Pharmacokinetic study immunosuppressive drug ( Tacrolimus , Everolimus Mycophenolate Sodium ) study population day 7 , 30 , 60 , 67 , 90 180 post-transplant . 2 . Serious adverse event ( internationally define ICH-GCP ) every year , five year . 3 . Biopsy proven acute rejection rat every year , five year . 4 . Identify renal filtration marker exist today , Cystatin C Serum Creatinine , adequate monitor renal function elderly transplant develop abbreviate equation eGFR day 7 . 5 . Evaluation metabolic effect ( bone density month 12 post-transplant ; vitamin D month 2 12 post-transplant ; gonadal function month 1 12 post-transplant ) Quality Life month 1 , 12 , 18 , 24 , 36 , 48 60 post-transplant study population . 6 . Left Ventricular Mass ( LVM ) Left Ventricle Ejection Fraction ( LVEF ) measure echocardiography end first year .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>All renal ( ) male female recipient age â‰¥ 60 , year undergo kidney transplantation living decease donor , include Expanded Criteria Donors ( ECD ) . Panel Reactive Antibody ( PRA ) &lt; 30 % . Patients consent participate study signing inform consent form transplant surgery 1st postoperative day ) . Allergy propose medication Patients active infection include HBV , HCV HIV .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>kidney transplantation</keyword>
	<keyword>chronic renal failure</keyword>
	<keyword>immunosuppressive therapy</keyword>
	<keyword>elderly</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>everolimus</keyword>
	<keyword>mycophenolate sodium</keyword>
	<keyword>serious adverse event</keyword>
	<keyword>biopsy</keyword>
	<keyword>Cystatin C</keyword>
	<keyword>metabolic effect</keyword>
	<keyword>Left Ventricular Mass ( LVM )</keyword>
	<keyword>Left Ventricle Ejection Fraction</keyword>
</DOC>